How do the various targeted therapy options like EGFR inhibitors, VEGF inhibitors, and BRAF inhibitors work? And...

According to the NCCN Guidelines for Colorectal Cancer, targeted therapy selection is primarily determined by specific biomarker testing of your tumor. Here's a breakdown:

1. EGFR Inhibitors (like cetuximab and panitumumab):

• According to ASCO Guidelines, these work by blocking epidermal growth factor receptors that cancer cells use to grow
• IMPORTANT: These are only recommended for patients with RAS wild-type tumors (no KRAS/NRAS mutations)
• The American Cancer Society notes that EGFR inhibitors are typically used in combination with chemotherapy or as single agents in later lines of therapy

1. VEGF Inhibitors (like bevacizumab):

• The National Cancer Institute explains these work by blocking blood vessel formation that feeds tumors
• According to NCCN Guidelines, these can be used regardless of tumor mutation status
• Can be combined with various chemotherapy regimens

1. BRAF Inhibitors:

• NCCN Guidelines specify these are only for patients with BRAF V600E mutations (found in about 8-10% of colorectal cancers)
• Usually combined with EGFR inhibitors and sometimes chemotherapy

Key Determining Factors: According to current NCCN Guidelines, your specific targeted therapy options will be determined by:

1. Molecular testing results (RAS, BRAF, MSI status)
2. Location of your tumor (left vs right side of colon)
3. Previous treatments and how you responded
4. Overall health status

Always remember that treatment decisions should be made in consultation with your oncology team, as they can evaluate all these factors in the context of your specific situation.

Sources:

• NCCN Guidelines for Colorectal Cancer (2023)
• ASCO Clinical Practice Guidelines for Metastatic Colorectal Cancer
• American Cancer Society's Targeted Therapy for Colorectal Cancer Guide